Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study.

Clinical and translational medicine

Truedsson M, Malm J, Barbara Sahlin K, Bugge M, Wieslander E, Dahlbäck M, Appelqvist R, Fehniger TE, Marko-Varga G.
PMID: 26951192
Clin Transl Med. 2016 Mar;5(1):9. doi: 10.1186/s40169-016-0086-5. Epub 2016 Mar 07.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is an irreversible disease, diagnosed predominantly in smokers. COPD is currently the third leading cause of death worldwide. Far more than 15 % of smokers get COPD: in fact, most develop some amount...

Cite
Truedsson M, Malm J, Barbara Sahlin K, et al. Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med. 2016;5(1):9doi: 10.1186/s40169-016-0086-5.
Truedsson, M., Malm, J., Barbara Sahlin, K., Bugge, M., Wieslander, E., Dahlbäck, M., Appelqvist, R., Fehniger, T. E., & Marko-Varga, G. (2016). Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clinical and translational medicine, 5(1), 9. https://doi.org/10.1186/s40169-016-0086-5
Truedsson, Mikael, et al. "Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study." Clinical and translational medicine vol. 5,1 (2016): 9. doi: https://doi.org/10.1186/s40169-016-0086-5
Truedsson M, Malm J, Barbara Sahlin K, Bugge M, Wieslander E, Dahlbäck M, Appelqvist R, Fehniger TE, Marko-Varga G. Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study. Clin Transl Med. 2016 Mar;5(1):9. doi: 10.1186/s40169-016-0086-5. Epub 2016 Mar 07. PMID: 26951192; PMCID: PMC4781824.
Copy Download .nbib Format: NLM
Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies.

Clinical and translational medicine

Malm J, Lindberg H, Erlinge D, Appelqvist R, Yakovleva M, Welinder C, Steinfelder E, Fehniger TE, Marko-Varga G.
PMID: 26272727
Clin Transl Med. 2015 Dec;4(1):67. doi: 10.1186/s40169-015-0067-0. Epub 2015 Aug 14.

BACKGROUND: In the postgenomic era, it has become evident that analysis of genetic and protein expression changes alone is not sufficient to understand most disease processes in e.g. cardiovascular and cancer disease. Biobanking has been identified as an important...

Cite
Malm J, Lindberg H, Erlinge D, et al. Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies. Clin Transl Med. 2015;4(1):67doi: 10.1186/s40169-015-0067-0.
Malm, J., Lindberg, H., Erlinge, D., Appelqvist, R., Yakovleva, M., Welinder, C., Steinfelder, E., Fehniger, T. E., & Marko-Varga, G. (2015). Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies. Clinical and translational medicine, 4(1), 67. https://doi.org/10.1186/s40169-015-0067-0
Malm, Johan, et al. "Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies." Clinical and translational medicine vol. 4,1 (2015): 67. doi: https://doi.org/10.1186/s40169-015-0067-0
Malm J, Lindberg H, Erlinge D, Appelqvist R, Yakovleva M, Welinder C, Steinfelder E, Fehniger TE, Marko-Varga G. Semi-automated biobank sample processing with a 384 high density sample tube robot used in cancer and cardiovascular studies. Clin Transl Med. 2015 Dec;4(1):67. doi: 10.1186/s40169-015-0067-0. Epub 2015 Aug 14. PMID: 26272727; PMCID: PMC4536244.
Copy Download .nbib Format: NLM
A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types.

Clinical and translational medicine

Kato Y, Nakamura H, Tojo H, Nomura M, Nagao T, Kawamura T, Kodama T, Ohira T, Ikeda N, Fehniger T, Marko-Varga G, Nishimura T, Kato H.
PMID: 26162278
Clin Transl Med. 2015 Dec;4(1):64. doi: 10.1186/s40169-015-0064-3. Epub 2015 Jul 03.

BACKGROUND: In the new pathologic classification of lung adenocarcinoma proposed by IASLC/ATS/ERS in 2011, lepidic type adenocarcinomas are constituted by three subtypes; adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and lepidic predominant invasive adenocarcinoma (LPIA). Although these subtypes...

Cite
Kato Y, Nakamura H, Tojo H, et al. A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types. Clin Transl Med. 2015;4(1):64doi: 10.1186/s40169-015-0064-3.
Kato, Y., Nakamura, H., Tojo, H., Nomura, M., Nagao, T., Kawamura, T., Kodama, T., Ohira, T., Ikeda, N., Fehniger, T., Marko-Varga, G., Nishimura, T., & Kato, H. (2015). A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types. Clinical and translational medicine, 4(1), 64. https://doi.org/10.1186/s40169-015-0064-3
Kato, Yasufumi, et al. "A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types." Clinical and translational medicine vol. 4,1 (2015): 64. doi: https://doi.org/10.1186/s40169-015-0064-3
Kato Y, Nakamura H, Tojo H, Nomura M, Nagao T, Kawamura T, Kodama T, Ohira T, Ikeda N, Fehniger T, Marko-Varga G, Nishimura T, Kato H. A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types. Clin Transl Med. 2015 Dec;4(1):64. doi: 10.1186/s40169-015-0064-3. Epub 2015 Jul 03. PMID: 26162278; PMCID: PMC4501340.
Copy Download .nbib Format: NLM
The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM).

Clinical and translational medicine

Chen X, Andersson R, Cho WC, Christiani D, Coico R, Drazen J, Ege M, Fehniger T, Gao H, Jin K, Liebman MN, Lopez E, Marraro G, Marko-Varga G, Marincola FM, Popescu LM, Spada C, Shahzad A, Wang E, Wang W, Wang X, Wang YX, Xia J, Qu J.
PMID: 23369397
Clin Transl Med. 2012 Aug 14;1(1):15. doi: 10.1186/2001-1326-1-15.

BACKGROUND: Supported by the International Society for Translational Medicine (ISTM), Wenzhou Medical College and the First Affiliated Hospital of Wenzhou Medical College, the International Conference on Translational Medicine (ICTM) was held on October 22-23, 2011 in Wenzhou, China. Nearly...

Cite
Chen X, Andersson R, Cho WC, et al. The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM). Clin Transl Med. 2012;1(1):15doi: 10.1186/2001-1326-1-15.
Chen, X., Andersson, R., Cho, W. C., Christiani, D., Coico, R., Drazen, J., Ege, M., Fehniger, T., Gao, H., Jin, K., Liebman, M. N., Lopez, E., Marraro, G., Marko-Varga, G., Marincola, F. M., Popescu, L. M., Spada, C., Shahzad, A., Wang, E., Wang, W., Wang, X., Wang, Y. X., Xia, J., & Qu, J. (2012). The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM). Clinical and translational medicine, 1(1), 15. https://doi.org/10.1186/2001-1326-1-15
Chen, Xiaoming, et al. "The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM)." Clinical and translational medicine vol. 1,1 (2012): 15. doi: https://doi.org/10.1186/2001-1326-1-15
Chen X, Andersson R, Cho WC, Christiani D, Coico R, Drazen J, Ege M, Fehniger T, Gao H, Jin K, Liebman MN, Lopez E, Marraro G, Marko-Varga G, Marincola FM, Popescu LM, Spada C, Shahzad A, Wang E, Wang W, Wang X, Wang YX, Xia J, Qu J. The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM). Clin Transl Med. 2012 Aug 14;1(1):15. doi: 10.1186/2001-1326-1-15. PMID: 23369397; PMCID: PMC3561055.
Copy Download .nbib Format: NLM
Medical marijuana utilization in gynecologic cancer patients.

Gynecologic oncology reports

Fehniger J, Brodsky AL, Kim A, Pothuri B.
PMID: 34258360
Gynecol Oncol Rep. 2021 Jun 24;37:100820. doi: 10.1016/j.gore.2021.100820. eCollection 2021 Aug.

BACKGROUND: Medical marijuana (MM) use is common among cancer patients, but relatively little is known about the usage patterns and efficacy of MM used by gynecologic cancer patients.METHODS: Demographic and clinical data were collected for gynecologic cancer patients prescribed...

Cite
Fehniger J, Brodsky AL, Kim A, et al. Medical marijuana utilization in gynecologic cancer patients. Gynecol Oncol Rep. 2021;37:100820doi: 10.1016/j.gore.2021.100820.
Fehniger, J., Brodsky, A. L., Kim, A., & Pothuri, B. (2021). Medical marijuana utilization in gynecologic cancer patients. Gynecologic oncology reports, 37100820. https://doi.org/10.1016/j.gore.2021.100820
Fehniger, Julia, et al. "Medical marijuana utilization in gynecologic cancer patients." Gynecologic oncology reports vol. 37 (2021): 100820. doi: https://doi.org/10.1016/j.gore.2021.100820
Fehniger J, Brodsky AL, Kim A, Pothuri B. Medical marijuana utilization in gynecologic cancer patients. Gynecol Oncol Rep. 2021 Jun 24;37:100820. doi: 10.1016/j.gore.2021.100820. eCollection 2021 Aug. PMID: 34258360; PMCID: PMC8255178.
Copy Download .nbib Format: NLM
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K.
PMID: 33986022
Clin Cancer Res. 2021 Jul 01;27(13):3744-3756. doi: 10.1158/1078-0432.CCR-21-0164. Epub 2021 May 13.

PURPOSE: Natural killer (NK)-cell recognition and function against NK-resistant cancers remain substantial barriers to the broad application of NK-cell immunotherapy. Potential solutions include bispecific engagers that target NK-cell activity via an NK-activating receptor when simultaneously targeting a tumor-specific antigen,...

Cite
Kerbauy LN, Marin ND, Kaplan M, et al. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30. Clin Cancer Res. 2021;27(13):3744-3756doi: 10.1158/1078-0432.CCR-21-0164.
Kerbauy, L. N., Marin, N. D., Kaplan, M., Banerjee, P. P., Berrien-Elliott, M. M., Becker-Hapak, M., Basar, R., Foster, M., Garcia Melo, L., Neal, C. C., McClain, E., Daher, M., Nunez Cortes, A. K., Desai, S., Inng Lim, F. W., Mendt, M. C., Schappe, T., Li, L., Shaim, H., Shanley, M., Ensley, E. L., Uprety, N., Wong, P., Liu, E., Ang, S. O., Cai, R., Nandivada, V., Mohanty, V., Miao, Q., Shen, Y., Baran, N., Fowlkes, N. W., Chen, K., Muniz-Feliciano, L., Champlin, R. E., Nieto, Y. L., Koch, J., Treder, M., Fischer, W., Okamoto, O. K., Shpall, E. J., Fehniger, T. A., & Rezvani, K. (2021). Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3744-3756. https://doi.org/10.1158/1078-0432.CCR-21-0164
Kerbauy, Lucila N, et al. "Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3744-3756. doi: https://doi.org/10.1158/1078-0432.CCR-21-0164
Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30. Clin Cancer Res. 2021 Jul 01;27(13):3744-3756. doi: 10.1158/1078-0432.CCR-21-0164. Epub 2021 May 13. PMID: 33986022; PMCID: PMC8254785.
Copy Download .nbib Format: NLM
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

Blood

Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA.
PMID: 34797911
Blood. 2021 Nov 19; doi: 10.1182/blood.2021011532. Epub 2021 Nov 19.

NK cells are a promising alternative to T cells for cancer immunotherapy. Adoptive therapies with allogeneic, cytokine-activated NK cells are being investigated in clinical trials. However, the optimal cytokine support after adoptive transfer to promote NK cell expansion, and...

Cite
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, et al. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2021;doi: 10.1182/blood.2021011532.
Berrien-Elliott, M. M., Becker-Hapak, M., Cashen, A. F., Jacobs, M. T., Wong, P., Foster, M., McClain, E., Desai, S., Pence, P., Cooley, S., Brunstein, C. G., Gao, F., Abboud, C. N., Uy, G. L., Westervelt, P., Jacoby, M. A., Pusic, I., Stockerl-Goldstein, K., Schroeder, M. A., DiPersio, J. F., Soon-Shiong, P., Miller, J. S., & Fehniger, T. A. (2021). Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, . https://doi.org/10.1182/blood.2021011532
Berrien-Elliott, Melissa M, et al. "Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2021011532
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2021 Nov 19; doi: 10.1182/blood.2021011532. Epub 2021 Nov 19. PMID: 34797911.
Copy Download .nbib Format: NLM
Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned.

Ecancermedicalscience

Granina E, Fehniger J, Kondziolka D, Silverman J, Downey A, Placantonakis D, Muggia F.
PMID: 32863877
Ecancermedicalscience. 2020 Jul 31;14:1083. doi: 10.3332/ecancer.2020.1083. eCollection 2020.

A 66-year-old woman with a history of stage IA mixed endometrioid and serous endometrial cancer presented to our centre with 2 weeks of worsening headaches nearly 4 years after her initial surgery. At admission, she manifested bitemporal hemianopsia, difficulty...

Cite
Granina E, Fehniger J, Kondziolka D, et al. Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned. Ecancermedicalscience. 2020;14:1083doi: 10.3332/ecancer.2020.1083.
Granina, E., Fehniger, J., Kondziolka, D., Silverman, J., Downey, A., Placantonakis, D., & Muggia, F. (2020). Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned. Ecancermedicalscience, 141083. https://doi.org/10.3332/ecancer.2020.1083
Granina, Evgenia, et al. "Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned." Ecancermedicalscience vol. 14 (2020): 1083. doi: https://doi.org/10.3332/ecancer.2020.1083
Granina E, Fehniger J, Kondziolka D, Silverman J, Downey A, Placantonakis D, Muggia F. Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned. Ecancermedicalscience. 2020 Jul 31;14:1083. doi: 10.3332/ecancer.2020.1083. eCollection 2020. PMID: 32863877; PMCID: PMC7434505.
Copy Download .nbib Format: NLM
Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy.

Gynecologic oncology reports

Fehniger J, Schiff PB, Pothuri B.
PMID: 30555884
Gynecol Oncol Rep. 2018 Nov 17;27:11-14. doi: 10.1016/j.gore.2018.11.004. eCollection 2019 Feb.

We describe a case of the first successful treatment of platinum refractory clear cell ovarian cancer with secondary cytoreductive surgery and placement of Calypso transponders to facilitate post-operative volumetric arc radiation therapy. In the setting of both primary and...

Cite
Fehniger J, Schiff PB, Pothuri B. Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy. Gynecol Oncol Rep. 2018;27:11-14doi: 10.1016/j.gore.2018.11.004.
Fehniger, J., Schiff, P. B., & Pothuri, B. (2019). Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy. Gynecologic oncology reports, 2711-14. https://doi.org/10.1016/j.gore.2018.11.004
Fehniger, Julia, et al. "Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy." Gynecologic oncology reports vol. 27 (2019): 11-14. doi: https://doi.org/10.1016/j.gore.2018.11.004
Fehniger J, Schiff PB, Pothuri B. Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy. Gynecol Oncol Rep. 2018 Nov 17;27:11-14. doi: 10.1016/j.gore.2018.11.004. eCollection 2019 Feb. PMID: 30555884; PMCID: PMC6275169.
Copy Download .nbib Format: NLM
Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine.

Clinical and translational medicine

Qian M, Wu D, Wang E, Marincola FM, Wang W, Rhodes W, Liebman M, Bai C, Lam CW, Marko-Varga G, Fehniger TE, Andersson R, Wang X.
PMID: 23369198
Clin Transl Med. 2012 Oct 24;1(1):25. doi: 10.1186/2001-1326-1-25.

BACKGROUND: Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from basic science to medical applications and entails a close collaboration among hospital, academia and industry.FINDINGS: This Session focused discussing on new models for project development and...

Cite
Qian M, Wu D, Wang E, et al. Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine. Clin Transl Med. 2012;1(1):25doi: 10.1186/2001-1326-1-25.
Qian, M., Wu, D., Wang, E., Marincola, F. M., Wang, W., Rhodes, W., Liebman, M., Bai, C., Lam, C. W., Marko-Varga, G., Fehniger, T. E., Andersson, R., & Wang, X. (2012). Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine. Clinical and translational medicine, 1(1), 25. https://doi.org/10.1186/2001-1326-1-25
Qian, Mengjia, et al. "Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine." Clinical and translational medicine vol. 1,1 (2012): 25. doi: https://doi.org/10.1186/2001-1326-1-25
Qian M, Wu D, Wang E, Marincola FM, Wang W, Rhodes W, Liebman M, Bai C, Lam CW, Marko-Varga G, Fehniger TE, Andersson R, Wang X. Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine. Clin Transl Med. 2012 Oct 24;1(1):25. doi: 10.1186/2001-1326-1-25. PMID: 23369198; PMCID: PMC3561049.
Copy Download .nbib Format: NLM
Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging.

Clinical and translational medicine

Végvári Á, Shavkunov AS, Fehniger TE, Grabau D, Niméus E, Marko-Varga G.
PMID: 26965929
Clin Transl Med. 2016 Mar;5(1):10. doi: 10.1186/s40169-016-0090-9. Epub 2016 Mar 10.

BACKGROUND: Tamoxifen is used in endocrine treatment of breast cancer to inhibit estrogen signaling. A set of stratified ER-positive and ER-negative tumor sections was subjected to manual deposition of tamoxifen solution in order to investigate its spatial distribution upon...

Cite
Végvári Á, Shavkunov AS, Fehniger TE, et al. Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clin Transl Med. 2016;5(1):10doi: 10.1186/s40169-016-0090-9.
Végvári, �. �., Shavkunov, A. S., Fehniger, T. E., Grabau, D., Niméus, E., & Marko-Varga, G. (2016). Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clinical and translational medicine, 5(1), 10. https://doi.org/10.1186/s40169-016-0090-9
Végvári, Ákos, et al. "Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging." Clinical and translational medicine vol. 5,1 (2016): 10. doi: https://doi.org/10.1186/s40169-016-0090-9
Végvári Á, Shavkunov AS, Fehniger TE, Grabau D, Niméus E, Marko-Varga G. Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clin Transl Med. 2016 Mar;5(1):10. doi: 10.1186/s40169-016-0090-9. Epub 2016 Mar 10. PMID: 26965929; PMCID: PMC4786513.
Copy Download .nbib Format: NLM
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.

Scientifica

Romee R, Leong JW, Fehniger TA.
PMID: 25054077
Scientifica (Cairo). 2014;2014:205796. doi: 10.1155/2014/205796. Epub 2014 Jun 25.

Natural killer (NK) cells are innate lymphoid cells important for host defense against pathogens and mediate antitumor immunity. Cytokine receptors transduce important signals that regulate proliferation, survival, activation status, and trigger effector functions. Here, we review the roles of...

Cite
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796doi: 10.1155/2014/205796.
Romee, R., Leong, J. W., & Fehniger, T. A. (2014). Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica, 2014205796. https://doi.org/10.1155/2014/205796
Romee, Rizwan, et al. "Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer." Scientifica vol. 2014 (2014): 205796. doi: https://doi.org/10.1155/2014/205796
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo). 2014;2014:205796. doi: 10.1155/2014/205796. Epub 2014 Jun 25. PMID: 25054077; PMCID: PMC4099226.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries